Novo Nordisk

Extracted Attributes

• Country

  Denmark

• Founded

  1923-01-01

• Founder

  August Krogh

• Industry

  Pharmaceuticals, Healthcare

• Employees

  78,387 (full-time)

• Legal Name

  Novo Nordisk A/S

• Headquarters

  Bagsværd, Denmark

• Market Presence

  168 countries

• Net Sales (2024)

  US$42.121 billion

• Valuation Status

  Highest-valued company in Europe

• Key Therapy Areas

  Diabetes, Obesity, Rare Disease, Hemostasis Management, Growth Hormone Therapy, Hormone Replacement Therapy, Cardiovascular & Emerging Therapy Areas

• Offices/Affiliates

  5 countries

• Majority Shareholder

  Novo Holdings A/S

• Production Facilities

  9 countries

• Key Products (Brand Names)

  Ozempic, Rybelsus, Wegovy (semaglutide), Levemir, Tresiba, NovoLog, Novolin R, Victoza, NovoSeven, NovoEight, NovoPen, FlexPen, Saxenda

• Sustainability Ranking (2012)

  Most sustainable company in the world by Corporate Knights

• Shares held by Novo Holdings A/S

  28.1%

• Market Capitalization Status (2023)

  Exceeded Denmark's GDP

• Voting Shares held by Novo Holdings A/S

  77.1%

Timeline

• One of the predecessor companies, Novo Terapeutisk Laboratorium, was founded. (Source: Wikidata, novonordisk.com)

  1923-01-01

• Novo Nordisk A/S was created through the merger of two Danish companies: Novo Industri A/S (formerly Novo Terapeutisk Laboratorium) and Nordisk Gentofte A/S (formerly Nordisk Insulinlaboratorium). (Source: summary, Wikipedia, DBpedia)

  1989

• Novo Nordisk Engineering (now NNE A/S) demerged from Novo Nordisk. (Source: web_search_results)

  1991

• Ranked 25th among Fortune's 100 Best Companies to Work For. (Source: Wikipedia, DBpedia)

  2010

• Named the most sustainable company in the world by the business magazine Corporate Knights. (Source: summary, Wikipedia, DBpedia)

  2012-01

• Ranked 72nd among Fortune's 100 Best Companies to Work For. (Source: Wikipedia, DBpedia)

  2014

• Ranked 73rd among Fortune's 100 Best Companies to Work For. (Source: Wikipedia)

  2017

• Market capitalization exceeded the GDP of Denmark's domestic economy, becoming the highest-valued company in Europe. (Source: summary, Wikipedia)

  2023

• Reported net sales of US$42.121 billion. (Source: summary, Wikipedia)

  2024

Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. Net sales in 2024 were US$42.121 billion.

Web Search Results

• Novo Nordisk - Wikipedia

  Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. [...] In 1989, Novo Industri A/S (Novo Terapeutisk Laboratorium) and Nordisk Gentofte A/S (Nordisk Insulinlaboratorium) merged to become Novo Nordisk A/S, the world's largest producer of insulin with headquarters in Bagsværd, Copenhagen. In 1991, Novo Nordisk Engineering (now NNE A/S) demerged after working as in-house consultants at Novo Nordisk for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. [...] Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

• Novo Nordisk AS Company Profile - GlobalData

  Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and delivering biological medicines for therapy areas for diabetes, haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. Its products include pre-filled delivery systems for insulin, glucagon hypokit, cartridge, needles, vials, insulin, estradiol for hormone replacement, recombinant drugs for haemophilia, glucagon, and [...] oral antidiabetic agents. The company offers its products to patients through brands such as NovoPen, FlexPen, Saxenda, and Ozempic. It markets products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

• Novo Nordisk in brief

  Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. ## Key facts Last updated: August 2025 (updated quarterly). ### Company overview [...] Legal name: Novo Nordisk A/S​ Founded: 1923​ President and CEO: Maziar Mike Doustdar Our heritage Meet Mike Executive management ### Making a difference Therapy areas: Diabetes, ​Obesity, Rare Disease, Cardiovascular & Emerging Therapy Areas​ Globally serving more than 45.2 million people living with serious chronic diseases​ Learn more about our therapy areas ### Workforce [...] ## Learn more about us What we do Our pipeline Our scientific approach Press releases Contact Media Relations ## We value your privacy

• Who we are | Novo Nordisk

  Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Our unordinary approach to driving changeOur approach reflects the way we balance scientific excellence with compassion, stay rooted in our Danish heritage while making a global impact, and remain ambitious while always putting people first. [...] Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Because we believe it takes an unordinary approach to drive real, lasting change in health. [...] Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no.24256790 _Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit ourproduct page_ Helpful links Report a side effect Patient help Supplier help Product list Contact us Annual Report ESG reporting Novo Nordisk Foundation Follow us

• Novo Nordisk A/S (NVO) Company Profile & Facts - Yahoo Finance

  cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. [...] Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products [...] ### Novo Nordisk A/S Novo Alle 1 Bagsvaerd, 2880 Denmark 45 44 44 88 88 Sector:Healthcare Industry:Drug Manufacturers - General Full Time Employees:78,387 ### Description

• Image

  

• Country

  Denmark

• Founder

  August Krogh

• Employees

  74,156

• Instance Of

  Q891723

• Headquarters

  Bagsværd

• Inception Date

  1/1/1923

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among 100 Best Companies to Work For in 2010 and 72nd in 2014 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth.